Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890 | 0.79 | — | — | |
| SCHEMBL1766721 | 0.79 | CA2 (0.42) | CA2CA1CA7CA13MMP1 | |
| SCHEMBL455847 | 0.76 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3100188 | 0.74 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3082432 | 0.74 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1146132 | 0.74 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL3090693 | 0.74 | CA2 (0.56) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL776245 | 0.72 | CA2 (0.44) | CA2CA1CA7CA13MMP1 | |
| SCHEMBL2634598 | 0.72 | CA2 (0.37) | CA2CA1CA7CA13 | |
| SCHEMBL9169461 | 0.72 | CA1 (0.30) | CA2CA1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233750-A | 3, 3-difluoro-1, 2,3, 6-tetrahydropyridine derivatives and preparation method thereof | 艾琪康医药科技（上海）有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-111233751-A | Preparation method of 3, 3-difluoro-4-aminopiperidine compound and derivative thereof | 丽水绿氟科技有限公司 | 2020-06-05 | — | — | CN | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| EP-2892343-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | claimed |
| WO-2014037349-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | claimed |
| EP-2101585-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Cenerx Biopharma, Inc. (US) | 2009-09-23 | — | — | EP | claimed |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | CENERX BIOPHARMA, INC. (US) | 2009-04-30 | — | — | US | claimed |
| WO-2008066874-A1 | DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | CENERX BIOPHARMA, INC. (US) | 2008-06-05 | — | — | WO | claimed |
| EP-4371979-A1 | FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT | Kumiai Chemical Industry Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117964674-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964673-A | Bridged artificial nucleic acid ALNA | 田边三菱制药株式会社 | 2024-05-03 | — | — | CN | disclosed |
| US-11964957-B2 | Pyrazole derivative and harmful organism-controlling agent | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2024-04-23 | — | — | US | disclosed |
| EP-3808738-B1 | PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENT | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2024-04-17 | — | — | EP | disclosed |
| CN-117693500-A | Carboxamide derivative and agricultural/horticultural plant disease control agent | 组合化学工业株式会社 | 2024-03-12 | — | — | CN | disclosed |
| EP-0143557-B1 | GRISEOLIC ACID DERIVATIVES, AND THEIR USE | SANKYO COMPANY LIMITED (JP) | 1988-12-21 | — | — | EP | disclosed |
| US-4783532-A | Process for preparing griseolic acid derivatives | SANKYO COMPANY LIMITED (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0283310-A1 | N-Benzhydryl-substituted heterocyclic derivatives, their preparation and their use | Sankyo Company Limited (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0214708-A2 | Griseolic acid derivatives, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4634706-A | BRAIN METABOLISM | SANKYO COMPANY LIMITED (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0143557-A2 | Griseolic acid derivatives, and their use | SANKYO COMPANY LIMITED (JP) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | CA2 341/4885CA1 1091/4885CA7 719/4885 |
| US-11964957-B2 | Pyrazole derivative and harmful organism-controlling agent | L3MBTL3, L3MBTL1, L3MBTL4 | CA2 1131/4885CA1 2251/4885CA7 2194/4885 |
| US-20090111813-A1 | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | PMP22, CNR2, COQ8A | CA2 814/4885CA1 719/4885CA7 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.